Neutrophil Extracellular Traps Promote Inflammatory Responses in Psoriasis via Activating Epidermal TLR4/IL-36R Crosstalk

Shuai Shao††, Hui Fang††, Erle Dang††, Ke Xue†, Jieyu Zhang†, Bing Li†, Hongjiang Qiao†, Tianyu Cao†, Yuchen Zhuang†, Shengxian Shen†, Tongmei Zhang†, Pei Qiao†, Caixia Li†, Johann E. Gudjonsson* and Gang Wang*†

† Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, China, † Department of Dermatology, University of Michigan, Ann Arbor, MI, United States

Epidermal infiltration of neutrophils is a hallmark of psoriasis, where their activation leads to release of neutrophil extracellular traps (NETs). The contribution of NETs to psoriasis pathogenesis has been unclear, but here we demonstrate that NETs drive inflammatory responses in skin through activation of epidermal TLR4/IL-36R crosstalk. This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression. Proinflammatory activity of NETs, and LCN2 induction, is dependent upon activation of TLR4/IL-36R crosstalk and MyD88/nuclear factor-kappa B (NF-κB) down-stream signaling, but independent of TLR7 or TLR9. Notably, both TLR4 inhibition and LCN2 neutralization alleviate psoriasis-like inflammation and NETs formation in both the IMQ model and K14-VEGF transgenic mice. In summary, these results outline the mechanisms for the proinflammatory activity of NETs in skin and identify NETs/TLR4 as novel therapeutic targets in psoriasis.

Keywords: psoriasis, neutrophil extracellular traps, IL-36, TLR4, keratinocyte

INTRODUCTION

Psoriasis is a chronic recurrent inflammatory skin disease with a complex pathogenesis (1, 2). It is generally considered that the main pathogenic driver of psoriasis is an intricate interplay between infiltrated inflammatory cells and activated keratinocytes (3, 4). While the roles of dendritic cells (DCs), T cells, and macrophages have been extensively investigated (5–8), the contribution of neutrophils, the most abundant leukocyte population of the immune system in humans, has remained unclear.

Neutrophils play a crucial role in a wide variety of conditions, including infections, autoimmune, neoplastic, and chronic inflammatory diseases (9–12). Presence of neutrophils is one of the hallmark histologic features of psoriasis, with neutrophils located both in the dermis and within the epidermis where they form small microabscesses as is seen in chronic plaque psoriasis, or larger intraepidermal neutrophilic collections characteristic of pustular psoriasis (2). No studies have comprehensively addressed the role of neutrophils in psoriasis, but neutrophil involvement is suggested by the results from several clinical studies, in which selective depletion of granulocytes and monocytes by adsorptive apheresis led to marked improvement in psoriasis symptoms (13, 14).
Neutrophils are very efficient phagocytes and this is central to their microbicidal role (15). In addition, neutrophils can be a major source of antimicrobial proteins (AMPs) such as S100A8/S100A9, cathelicidin (LL37) and lipocalin2 (LCN2), all of which can participate in and amplify inflammatory responses (16–19). Neutrophils may also undergo a cell death process called NETosis upon activation, in which they extrude their nuclear material into the extracellular space (20, 21). These structures called neutrophil extracellular traps (NETs) are large, web-like structures composed of decondensed DNA, histones, and granule proteins (22), and their presence has been described in psoriatic skin, where they may act by inducing increased expression of human β-defensin-2 (23). In short, neutrophils and NETs can contribute to inflammation through several different mechanisms, through inflammasome activation (24), triggering of TLR7 and TLR9 by self-antigen complexes such as LL37, S100A8/S100A9, cathelicidin (LL37) and lipocalin2 (LCN2), all of which can participate in and amplify inflammatory responses (25), promoting macrophage pyroptosis (26), or through processing and activation of IL-36 cytokines (27, 28).

Based on these considerations, we explored the mechanisms by which neutrophils and NETs affect the pathogenesis of psoriasis. We confirm that psoriatic neutrophils are activated and form NETs in psoriasis patients compared to healthy controls. Using both in vivo and in vitro approaches, we demonstrate that neutrophils, through release of NETs, amplify skin inflammation through activation of IL-36 and toll-like receptor 4 (TLR4) signaling. Furthermore, IL-36 and TLR4 signaling act synergistically to induce expression of the neutrophil chemoattractant LCN2 in keratinocytes, further increasing neutrophil infiltration into the skin, and thereby amplifying the inflammatory cascade. These results demonstrate a major role for neutrophils and NETs in amplifying skin inflammation and identify NETs/TLR4 as novel therapeutic targets in psoriasis.

**MATERIALS AND METHODS**

**Patients and Samples**

All analyses of human materials were performed in full agreement with institutional guidelines, with the approval of the Ethical committee of the Fourth Military Medical University (reference number KY20173053-1), and conducted according to the principles in the Declaration of Helsinki. Informed consent to collect blood and skin lesions were obtained from all subjects enrolled in the study.

We chose psoriasis patients (twenty-five men and seventeen women, age ranged from 18 to 59 years with mean of 35.6 years old) who visited our Department at Xijing Hospital without any other systemic diseases or any systemic treatment for a minimum of 6 weeks. Normal control blood samples were collected from age- and sex- matched healthy volunteers working at our Department (sixteen men and twenty-two women, age ranged from 25 to 42 years with mean of 30.4 years old). Control skin biopsies were obtained from discarded healthy skin from donors (one men and three women, age ranged from 21 to 45 years with mean of 29.1 years old) who were admitted to the Department of Plastic Surgery at Xijing Hospital.

**Microarray Data Processing and Analysis**

Total RNA containing small RNA was extracted from peripheral neutrophils of psoriasis patients and healthy controls ($n = 3$ for each group) by using the trizol reagent (Invitrogen). The Affymetrix PrimeView Human Gene Expression Array was used in this study and performed by CapitalBio Corporation (Beijing, China). The scanned images were assessed and analyzed to generate raw data files saved as CEL files using Affymetrix GeneChip Operating software (GCO 1.4). The quality of each CEL file was assessed using Affymetrix Expression Console Software according to the Affymetrix standard protocol. And the increase/decrease of gene expression in neutrophils from psoriasis patients compared with those from healthy controls was calculated as a log2-fold change to obtain a symmetric distribution around zero. For functional clustering, genes were annotated with Gene Ontologies (www.geneontology.org/).

**Mouse Experiments**

The animal studies were approved by the institutional review board, and carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals. Female BALB/c mice aged 6 to 8 weeks used for these studies were obtained from the Department of Laboratory Animal Medicine of the Fourth Military Medical University and bred and housed individually in a specific pathogen-free barrier facility. Mice were randomly assigned to groups of three mice each, and received Cl-amidine (10 mg/kg/d, 10599; Cayman Chemical) or DNase I (10 mg/kg/d, 18068-015; Invitrogen) or an equal volume of PBS by daily intravenous injection (29, 30) 4 h prior to imiquimod (IMQ) induction. The mice then received a daily topical dose of 6.25 mg IMQ cream (Inova Pharmaceuticals) or Vaseline on the shaved back for consecutive 7 days.

To investigate the role of TLR4 signaling in psoriasis, we used cream base to blend the siRNA targeting TLR4 (0.5 nmol in 1 mg emulsion matrix/ear, Ribobio) or TLR4 inhibitor TAK-242 (0.5 mg in 1 mg emulsion matrix/ear, A8350; APEXBio). For each mouse, the ears were applied with TLR4 siRNA, control (NC) siRNA, TAK-242 or DMSO mixed with emulsion matrix every morning, and the right ears were injected with murine PMA NETs (isolated from PMA treated murine neutrophils; 25 μg/ear) subcutaneously every other day and the left with same volume of culture medium from unstimulated murine neutrophils. Both ears were also treated with 4 mg IMQ or Vaseline daily for consecutive 7 days.

To evaluate the pathogenic role of LCN2 in psoriasis, anti-LCN2 mAb (100 μg/mouse, MAB1857; R&D Systems) or rat IgG2a isotype control antibody (100 μg/mouse, MAB006; R&D Systems) were intraperitoneally (i.p.) injected 4 h prior the first IMQ induction and every 48 h thereafter. Shaved mouse dorsal skin was treated daily with IMQ cream or Vaseline for 7 days. In addition, K14-VEGF mice were provided by the Department of Pharmacy in Changhai Hospital, and were i.p. injected with anti-LCN2 mAb or isotype control antibody every 48 h for consecutive 14 days.

Blood was collected by the tail-vein approach on day 7, and serum was stored at $−80^\circ$C for later ELISA.
MPO-DNA Enzyme-Linked Immunosorbent Assay (ELISA)

To quantify NETs in human serum, we employed a capture ELISA based on MPO associated with DNA. For the capture antibody, 5 μg/ml anti-MPO mAb (07-496; Upstate) was coated onto 96-well-plates at 4°C overnight. After washing 3 times (300 μl each), 50 μl of serum samples was added to the wells with 50 μl incubation buffer containing a peroxidase-labeled anti-DNA mAb in Cell Death ELISAPLUS kit (1:25, Roche). The plate was incubated for 4 h, shaking at 300 rpm at room temperature. After 3 washes (300 μl each), 100 μl peroxidase substrate (ABTS) was added to incubate at room temperature in the dark for 20 min. Then absorbance at 405 nm wavelength was measured.

NETs Generation

2 × 10⁶ neutrophils were seeded in 12-well-plates in serum-free Roswell Park Memorial Institute (RPMI) (Gibco) and were then stimulated to release NETs by phorbol 12-myristate 13-acetate (PMA) (50nM, P1585; Sigma) for 4 h at 37°C. Afterwards, the medium was carefully removed and the cell layer was washed softly with 2 ml PBS without Ca and Mg. Then the washing PBS was collected after vigorous agitation and centrifuged for 10 min at 450 g at 4°C and cell-free NETs structures were collected in supernatant phase.

Mass Spectrum of Contents of NETs

For NETs protein isolation, isolated 2 × 10⁶ neutrophils were seeded in 12-well-plates in serum-free RPMI (Gibco) and were then stimulated to release NETs by PMA (50 nM, Sigma) for 4 h at 37°C. Supernatant was removed and each was washed carefully with RPMI. NETs were then digested with 10U/ml DNase I (Invitrogen) for 20 min, and ethylenediaminetetraacetic acid (EDTA; 5 mM, Invitrogen) was used to block the activity of DNase I. Samples were then centrifuged at 300 g to remove whole cells and 16,000 g to remove debris. Then 85 μg of proteins of PMA-induced NETs from psoriatic neutrophils were identified using Nano-LC/MALDI-MS (Capitalbio Technology Corporation).

Primary Human Keratinocytes Culture and Stimulation

Foreskin keratinocytes were obtained from anonymized donors. The study was approved by the ethics committee of the Fourth Military Medical University and conducted according to the principles of Declaration of Helsinki. Informed written consent was given by every patient or their parents. In short, skin specimens were cleaned of adipose tissue, cut into small fragments and then incubated in Dispase II (D4693; Sigma) at 37°C for 30 min. The epidermal layer containing keratinocytes was carefully separated from the dermis using fine forceps, and 0.25% trypsin–EDTA (Gibco) was added for 12 min at 37°C to release epidermal keratinocytes. The trypsin reaction was neutralized by addition of 10% FBS. Following centrifugation (190 g for 10min), the cell pellet was collected.

Then keratinocytes were cultured in a serum-free Keratinocyte-SFM Media Kit (containing 0.125 μg/ml epidermal growth factor) (Gibco) in a humidified 5% CO₂ incubator, and passage 3 to 4 cells were used for experiments. In short, cells at 50 to 70% confluency were stimulated for different time periods with NETs (1 μg/ml, 5 μg/ml, 10 μg/ml), recombinant Histone3 (5 μg/ml, ab132921; Abcam), S100A8 (10 μg/ml, 11138-H08B; Sino Biological), S100A9 (10 μg/ml, 11145-H08B; Sino Biological), HSP70 (10 μg/ml, 11660-H07H; Sino Biological), LCN2 (10 μg/ml, ab175463; Abcam). To inhibit PAD4 activity, neutrophils were pretreated with Cl-aminide (100 μM; Cayman, MI, USA) for 15 min. In another experiment of cell stimulation, IL-36γ (100 ng/ml, 10124-HNCE1; Sino Biological) and IL1β (50 ng/ml, GMP-10139-HNAE; Sino Biological), IL36R (2 μg/mL, AF269; R&D), and IL1RI antibodies (2 μg/mL, AF269; R&D) were also used.

Statistical Analysis

For statistical analysis, data obtained from at least three independent experiments were performed using GraphPad Prism software versions 6 (GraphPad software, San Diego, CA, USA). Statistical significance was determined using Student's unpaired two-tailed t test or analysis of variance (ANOVA) as indicated in the legend (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Flow cytometry data was analyzed using Flowjo v10. The number of sampled units, n, is indicated in the Figure legends.

The other methods can be found in Supplemental Materials and methods. The information of primers used in this study was listed in Table S2.

RESULTS

Psoriatic Neutrophils Are Pre-activated and Form NETs

To explore neutrophil participation in psoriasis pathogenesis, we compared cell viability of neutrophils in psoriasis patients against healthy controls. Psoriasis neutrophils underwent spontaneous death at a higher rate than healthy neutrophils in vitro (Figure 1A; Figure S1A). To understand the underlying cause of this accelerated death and identify additional differences between psoriasis neutrophils and healthy ones, we analyzed microarray gene expression data from peripheral neutrophils from three psoriasis patients and three healthy controls (GEO: GSE106087). Using Gene ontology analysis, the differentially expressed genes (DEGs) in psoriasis vs. healthy neutrophils could be assigned to various inflammatory functions, including "chemotaxis," “response to stimulus," and "leukocyte activation," indicating that circulating neutrophils are pre-activated in psoriasis patients. KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways analysis demonstrated the enrichment for "cytosolic DNA-sensing pathway," "NF-kB signaling pathway," and "Toll-like receptor signaling pathway" (Figure 1B). Moreover, the top upregulated genes were verified by quantitative real-time polymerase chain reaction (qRT-PCR) (Figure 1C). These increased DEGs found in psoriasis neutrophils were genes encoding for enzymes, proteases, and cathelicidin which have been shown to be indispensable components and inducers of
NETs formation (22, 31). Therefore, we explored the presence of NETs in psoriasis patients by quantification of circulating MPO-DNA complexes, which showed significant increase in serum of psoriasis patients compared to healthy individuals (Figure 1D). Using cell immunofluorescence, we demonstrated that interleukin (IL)-17A, tumor necrosis factor (TNF)-α, high mobility group box-1 (HMGB1), and LCN2, all of which are elevated in psoriasis (4, 19, 32), were potent inducers of NETs formation, and comparable to induction by phorbol 12-myristate 13-acetate (PMA), which was used as a positive control (Figure S1B). These data demonstrate that neutrophils are pre-activated and primed to form NETs in psoriasis patients.

Targeting NETs Attenuates Psoriasis-Like Inflammation in vivo

Similar to what was seen in human psoriasis (23), NETs were also detected in the skin lesions of IMQ mice (Figure S2A). To address the potential pathogenic role of NETs in this model, we treated IMQ mice with either CI-amidine, an inhibitor of peptidyl-arginine deaminase 4 (PAD4) that required in NETs formation (30), or DNase I to break down NETs. In the IMQ-induced mouse model, intravenous injection of CI-amidine or DNase I over a 7-day period resulted in decreased scaling, decreased acanthosis, and decreased inflammatory infiltrate, as observed by visual inspection and hematoxylin-eosin (H&E)-staining (Figures 2A,B). QRT-PCR analysis of inflamed back skin from IMQ mice revealed significantly lower expressions of Lcn2, Il36g, Il17a, Cxcl1, and Ccl20 in the CI-amidine- or DNase I-treated group compared to vehicle control (Figure 2C). Accordingly, the number of infiltrated T cells and neutrophils in the dermis were markedly decreased following CI-amidine or DNase I treatment (Figures 2D,E; Figure S2B). Importantly, the circulating MPO-DNA complexes indicating NETs level in serum was also reduced by CI-amidine or DNase I administration in IMQ mice (Figure 2F). Together, these data show that NETs can be targeted to treat psoriasis inflammation.
FIGURE 2 | Targeting NETs attenuates psoriasis-like inflammation in vivo (A) The phenotype and H&E staining of back skin from CI-amidine, DNase I, or PBS-administrated mice with IMQ or Vaseline treatment, three mice per group. Scale bars, 100 µm. (B) Quantification of epidermal thickening and infiltrated immunocytes according to H&E staining in a One-way ANOVA, n = 8 per group (mean±SD). (C) QRT-PCR analyses of psoriasis-related cytokines and molecules from skin samples of mice described as in A One-way ANOVA, n = 8 per group (mean±SD). (D, E) Representative immunofluorescence and quantification of skin sections from CI-amidine, DNase I, or PBS-treated IMQ mice for neutrophil marker Ly-6G and T cell marker CD4. Scale bars, 100 µm. One-way ANOVA, n = 8 per group (mean±SD). (F) The MPO-DNA complex quantification indicating NETs level in serum from psoriasis patients and normal controls, n = 8, each data point represents an individual. One-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All the bars represent the average of three independent experiments.
NETs Activate Inflammatory Responses in Keratinocytes

As NETs are primarily located in close proximity to keratinocytes within psoriatic lesions (23), we wanted to determine whether NETs could directly activate keratinocytes to promote skin inflammation. To address this, we exposed human primary keratinocytes to purified PMA-induced NETs at different concentrations for 24 h, and compared against keratinocytes exposed to culture medium from unstimulated neutrophils (Figure S3A). NETs-induced genes in keratinocytes included LCN2, IL36G, and chemokines including CXCL8, CXCL1, and CCL20 (Figure 3A). In addition, NETs-stimulated keratinocytes released more LCN2, CXCL8, CXCL1, and IL-36γ protein into the culture medium than did control group (Figure 3B). Immunofluorescence showed marked expression of LCN2, CXCL8, CXCL1, and IL-36γ in psoriatic skin, but not in normal controls (Figure S3B).

We further analyzed the protein composition of PMA-induced NETs formed by psoriatic neutrophils using liquid chromatography followed by mass spectrometry (Table S1). Among them, S100A9, S100A8, LCN2, and HSP70 (HSPA1A) were amongst the most highly enriched proteins in NETs (Figure 3C). Considering that these molecules might independently contribute to keratinocyte activation, we treated keratinocytes with NETs and compared against keratinocytes treated with recombinant S100A9, S100A8, LCN2, and HSP70 proteins. QRT-PCR results confirmed our previous finding that NETs robustly up-regulated expression of LCN2, and IL36G, CXCL1, and CXCL8 in keratinocytes, whereas minimal responses were seen with each of the recombinant proteins (Figure 3D). Notably, when NETs formation was blocked by CI-amidine, their stimulatory effects on keratinocytes was significantly weakened (Figure 3E). Collectively, these data indicate that NETs work as an integrated unit to activate keratinocytes in psoriasis.

TLR4/MyD88/TRAF6/TAK1 and NF-κB Signaling Mediate the NETs-Induced Immune Responses

LCN2, the most highly expressed inflammatory mediator in NETs-treated keratinocytes, has been reported previously by our group to be abundant in the skin lesions of psoriasis patients and modulate neutrophil functions (19). Therefore, we chose LCN2 as a target to dissect the mechanisms by which NETs activated keratinocytes. At the frontline of innate immune surveillance are the pattern recognition receptors (PRRs) which are known to function as receptors for some of the proteins enriched in NETs (33). Considering that NETs are web-like structures, we focused on PRRs on plasma membrane which were reported to be significantly increased in psoriatic lesions, including TLR2, Dectin-1, and TLR4 (33, 34). Our results showed that the expressions of TLR4 was up-regulated more than 4-fold in keratinocytes stimulated by NETs (Figure 4A). Moreover, TLR4 expression was increased and primarily located in the epidermis of psoriatic skin, but with weak epidermal expression in healthy controls (Figure 4B). The exposure of keratinocytes to NETs (5 μg/mL) markedly increased the expressions of MyD88, TLR4, and IL-36γ, and led to production of LCN2 in keratinocytes.

TLR4 Activation Synergizes With IL-36γ to Induce Pro-inflammatory Gene Expressions

Several reports have indicated an important role for IL-36, particularly IL-36γ, in psoriasis pathogenesis, as a potent pro-inflammatory mediator (39, 40), and as a valuable biomarker of disease activity (41). Recently, it is demonstrated that NETs associated proteases can process and activate IL-36 cytokines and amplify inflammatory responses in skin (28). Therefore, we assessed whether IL-36γ secreted by keratinocytes played a role in NETs-induced immune responses. QRT-PCR results showed that LCN2 and IL-36γ mRNA was highly induced in keratinocytes treated with bioactive IL-36γ or IL-1β (as a positive control) compared to unstimulated control (Figure 5A). Importantly, the up-regulation of LCN2, IL-36G, CXCL1, CXCL8, and CCL20 in keratinocytes stimulated by NETs was largely inhibited by IL-36R blockade (Figures 5B,C).

To determine a potential cross-talk between IL-36 and TLR4 signaling, we used low-dose LPS as a proxy for neutrophil-derived TLR4 endogenous ligands. QRT-PCR results demonstrated that IL-36γ synergized with TLR4 activation to promote increased LCN2 mRNA expression in keratinocytes (Figure 5D). In addition, both mRNA and protein expressions of TLR4, along with the adaptor molecule MyD88 were strongly induced by IL-36γ or IL-1β (as a positive control) (Figures 5E,F). Notably, IL-36R blockade inhibited both TLR4 expression and MyD88 activation in keratinocytes co-cultured with NETs (Figures 5G,H). These data suggest that IL-36γ, secreted by NETs-stimulated keratinocytes, induces TLR4 expression, priming keratinocytes to respond to NETs, and subsequently activates the inflammatory response.
synergizes with TLR4 activation to stimulate keratinocytes to highly express LCN2.

**Inhibition of TLR4 Function Ameliorates NETs-Exacerbated Skin Inflammation in vivo**

Next, we explored the therapeutic potential of TLR4 inhibition for NETs-exacerbated psoriasis-like inflammation in the IMQ mouse model (Figure S5A). Topical treatment with siRNA targeting TLR4 for 7 consecutive days significantly attenuated acanthosis and immune cell infiltration in ears of the IMQ-treated group, with or without NETs injection (Figures 6A,B; Figures S5B,C). Likewise, expressions of downstream signaling molecules including MyD88 and phosphorylated NF-κB p65 were decreased accordingly (Figure 6C; Figure S5D). Consistent with these findings, qRT-PCR demonstrated decrease in mRNA expressions of Lcn2
FIGURE 4 | TLR4/MyD88/TRAF6/TAK1 and NF-κB signaling mediate the NETs-induced immune responses (A) QRT-PCR for TLR2, TLR4, and Dectin1 with cDNA from cultured keratinocytes stimulated with NETs. Data are expressed as means ± SD (n = 3). Two-way ANOVA. (B) Tissue immunofluorescence analysis of the location and expression of TLR4 in the skin lesions of psoriasis patients and normal controls. Scale bars, 100 µm. (C) The protein expressions of downstream adaptor molecules of TLR4 in NETs-stimulated keratinocytes. (D) The phosphorylation level of phospho-NF-κB p65 and total proteins at indicated time following NETs stimulation in primary keratinocytes. (E) The phosphorylation level of NF-κB p65 in TLR4- or MyD88-silenced keratinocytes with NETs stimulation for 30min. (F) LCN2 expression in TLR4-, MyD88-, or NF-κB p65-silenced keratinocytes with NETs stimulation. (G) The mRNA levels of LCN2 and IL36G in TLR7- or TLR9-silenced keratinocytes followed by NETs stimulation. One-way ANOVA, data are expressed as means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant. All experiments were repeated for at least three times.

and IL17A following TLR4 silencing (Figure 6D; Figure S5E). Furthermore, daily topical treatment with the TLR4 inhibitor TAK-242 also reduced the severe psoriasis phenotype in IMQ mouse model (Figures 6E–G). These in vivo results demonstrate that the TLR4/MyD88/NF-κB-dependent signaling pathway is aberrantly activated in keratinocytes by NETs, and that targeting of this pathway can lead to improvement in psoriasis-like inflammation.

To address the potential role of LCN2 in this process, we neutralized LCN2 using antibody in two mouse models of psoriasis (Figure S6A), the IMQ model and the transgenic K14-VEGF model (42, 43), and
FIGURE 5 | TLR4 activation synergizes with IL-36γ to induce inflammatory gene expression (A) The mRNA expressions of LCN2 and IL36G in keratinocytes stimulated with recombinant IL-36γ (100 ng/ml) or IL-1β (50 ng/ml) for 24 h. (B,C) The mRNA levels of LCN2, IL36γ, and other inflammatory mediators in keratinocytes co-cultured with NETs and anti-IL36R or not. (D) The mRNA expression of LCN2 in keratinocytes stimulated with IL-36γ and LPS. (E,F) The mRNA and protein levels of TLR4 and activation of MyD88 in cultured keratinocytes stimulated with IL-36γ or IL-1β for indicated time. (G,H) The mRNA and protein levels of TLR4 and activation of MyD88 in keratinocytes co-cultured with NETs and anti-IL36R or not for indicated time. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA, n = 3 (mean ± SD). All the bars represent the average of three independent experiments.
FIGURE 6 | Inhibition of TLR4 function ameliorates NETs-exacerbated skin inflammation in vivo. (A) Representative H&E analysis of the ears on day 7. TLR4 or control siRNA within the cream were applied to the ears of BALB/c mice daily, and NETs were subcutaneously injected back every 48 h. Scale bar = 100 µm. The study involved 3 mice per group and 3 independent experiments. (B) The analysis of skin thickening and inflammatory cell infiltration. Two-way ANOVA, n = 8 (mean ± SD).

(C) Ear dermis and epidermis were separated. Western blot analysis of MyD88 and phosphorylated p65 expressions in the epidermis of ears after treatment as in A. (D) The mRNA level of Lcn2 and Il17a in the epidermis of mice subjected to indicated administration as in A. Two-way ANOVA. Values represent the means ± SD (n = 3).

(E) Histological sections of mouse ears on day 7. TAK-242 or DMSO within the cream were applied to the inside ear of BALB/c mice daily, and NETs were subcutaneously injected back every 48 h. Scale bar = 100 µm, n = 3 per group. (F) Statistical analysis of the epidermal thickness and infiltrated cells in dermis. Two-way ANOVA, n = 8 (mean ± SD).

(Continued)
**FIGURE 6 | (H)** Representative H&E staining, infiltrated neutrophils labeled by Ly-6G, and immunofluorescence staining NETs structure in back skin from control IgG or LCN2 mAb treated IMQ mice, n = 5 per group. Scale bar: 100 µm. (I) Statistical analysis of Ly-6G labeled cells in H. Two-tailed Student’s t-test, n = 8 (means ± SD). (J) Statistical analysis in back skins of control IgG or LCN2 mAb treated IMQ mice. Two-tailed Student’s t-test, n = 3 (means ± SD). Scale bar = 100µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All the bars represent the average of three independent experiments.

**FIGURE 7 |** Proposed model of the NETs-TLR4/IL-36R-keratinocyte amplification loop in psoriasis. In psoriasis, neutrophils infiltrating the epidermis undergo NETosis in close proximity to keratinocytes. NETs stimulate keratinocytes to produce high levels of various inflammatory mediators, including LCN2, IL-36γ, CXCL8, and CXCL1. Secreted and activated IL-36γ induces TLR4 expression. Endogenous neutrophils-derived TLR4 ligands then synergize with IL-36γ, signaling through MyD88 and NF-κB activation, to induce LCN2 and IL-36γ production. In turn, the up-regulated LCN2 modulates NETs formation and neutrophil migration, enhancing and sustaining the inflammatory response. Thus, targeting NETs/TLR4 may provide a novel therapeutic approach for the treatment of psoriasis.

After 7 or 14 consecutive days, marked reduction in acanthosis and the number of Ly-6G labeled neutrophils was observed (Figures 6H,I; Figures S6B–D). Notably, administration of LCN2 neutralizing antibody significantly reduced formation of NETs in skin lesions of IMQ mice (Figures 6H,J). In summary, these data suggest that LCN2, secreted by activated keratinocytes and neutrophils, is a critical inflammatory factor down-stream of TLR4/IL-36R that participates in and sustains NETs-exacerbated psoriasis inflammation.

**DISCUSSION**

In this study, we confirm that circulating neutrophils are found in a pre-activated state in psoriasis, contributing to the high NETs level in patients. Furthermore, using a commonly used mouse model of psoriasis-like inflammation (44), we demonstrate that neutrophils have a major contribution to psoriasis-like inflammation heightening IL-17A and IL-36 responses, which is dependent upon NETs release and function. In addition, NETs interact directly with keratinocytes and activate an TLR4/IL-36R crosstalk with subsequent activation of the MyD88/NF-κB signaling pathway. This in turn leads to increased expressions of multiple pro-inflammatory cytokines and chemokines, most notably LCN2, which results in increased accumulation of immunocytes, including neutrophils, and amplification and sustenance of the inflammatory cascade in psoriasis (Figure 7).

The proteome of NETs, or “NETome,” has been reported to be regulated under different physiological conditions, which may affect their roles in inflammation (45). Many of the protein components of NETs, which have been explored in several studies (31, 46), including S100A8, S100A9, LCN2, and HSP70 that have been previously shown to have potent pro-inflammatory properties (17, 18, 47, 48). In contrast, our study shows minimal direct impact of these proteins on keratinocytes, and much less...
than that seen with intact NETs, suggesting that full integrity of NETs is required for eliciting their full pro-inflammatory effect in psoriasis. Several studies have addressed the effect of intact NETs on inflammatory responses. This includes activation of trypsin in acute pancreatitis (49, 50), priming of T cells through reduction in their activation threshold (51), and triggering of macrophages for cytokine release in atherosclerotic plaques (52). The studies that have looked at the role of NETs in psoriasis have been limited to plasmacytoid DCs (pDCs), demonstrating that NETs, through sensing of NETs derived DNA by TLR9, promote production of type I interferons to initiate inflammation in psoriasis (53, 54).

In psoriatic skin, NETs are mainly detected in close vicinity to keratinocytes, however, beyond one study showing induction of β-defensin-2 by NETs (23), no studies have addressed the broader effects of NETs on keratinocytes or the mechanisms involved. In striking contrast to pDCs, neither TLR7 or TLR9 contribute to NET induced activation of keratinocytes. In addition to being composed of DNA, histones, and S100A proteins, NETs carry a range of proteases, including cathepsin, elastase, and proteinase-3 (28). These proteases have been shown to activate IL-36 cytokines, which are expressed and secreted by keratinocytes as inactive precursor, thereby increasing their biologic activity about 500-fold (28). IL-36 cytokines are highly expressed in both chronic plaque psoriasis (55) and pustular psoriasis (39), and IL-36 signaling has been shown to be essential for development of psoriasis-like inflammation in the IMQ mouse model (56). This is consistent with our findings, which show that IL-36 signaling is necessary for the pro-inflammatory effect of NETs. Thus, NETs, through activation of IL-36 cytokines and IL-36R signaling, promote the expression of TLR4, which can bind endogenous ligands such as S100A8, S100A9, and HSP70 (57, 58) that are abundantly expressed in neutrophils and NETs. This IL-36/TLR4 cross-talk can explain the findings from a recent report that shows that targeting and inhibition of TLR4 prevents development of autoinflammatory symptoms in a mouse model of pustular psoriasis caused by deficiency of the IL-36 receptor antagonist (59), but mutations in the IL-36 receptor antagonist have been shown to predispose to generalized pustular psoriasis (60, 61).

LCN2 is a prominently expressed gene in psoriasis (19, 62), and is one of the genes most prominently induced by NETs in keratinocytes. In our previous work, we have demonstrated that LCN2 potentiates inflammation by acting as a chemoattractant and as a trigger for neutrophil activation in psoriasis (19). Importantly, IMQ mice treated with neutralizing LCN2 antibody had decreased number of neutrophils, as well as decreased number of NETs in inflamed skin. Therefore, neutrophils, through release of NETs in the epidermis, set up a self-sustaining loop in which increased expression and secretion of LCN2, by NETs-stimulated keratinocytes, continuously attracts more neutrophils into the skin, leading to even greater increase in NETs levels in skin, thereby propagating the inflammatory process. This is likely to both amplify and sustain neutrophil-driven inflammatory responses in psoriasis and pustular psoriasis.

In addition to providing novel insights into neutrophils immune responses in skin, our findings may also offer novel therapeutic targets for psoriasis. Dimethyl fumarate, which has been used to treat psoriasis successfully, showed inhibitory effect on NETs formation (63). Target PAD4 to inhibit NETs formation has recently been shown to be protective in murine model of lupus, diabetes, and atherosclerosis, without any notable adverse events (30, 64, 65). In addition, DNase I treatment, that breaks up NETs structures may also have a therapeutic potential (66, 67). In our mouse experiments, both CI-amidine and DNase I treatment improved psoriasis-like manifestations, confirming that NETs can be a treatment target for psoriasis patients. In addition, as seen with the marked improvement in our model with both TLR4 inhibition, and LCN2 blockade, these provide additional novel therapeutic targets in both chronic plaque and pustular psoriasis.

In conclusion, we demonstrate NETs as the critical link between neutrophil infiltration and keratinocyte activation in psoriasis. As neutrophil infiltration into epidermis is found in many other inflammatory conditions, including lupus and bullous pemphigoid, the findings described here are likely to have implications beyond psoriasis alone. Furthermore, our data provide a rational basis for development of therapies specifically targeting the autoinflammatory loop of NETs-keratinocytes-IL-36 in psoriasis and identify TLR4 as novel therapeutic targets in psoriasis.

**ETHICS STATEMENT**

All mouse experiments described in this study were approved by the institutional review board and carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals. The protocol was approved by the committee of the Fourth Military Medical University. All efforts were made to minimize suffering and ensure the highest ethical and humane standards. All analyses of human materials were performed in full agreement with institutional guidelines, with the approval of the Ethical committee of the Fourth Military Medical University (reference number KY20173053-1) and conducted according to the principles in the Declaration of Helsinki. Informed consent to collect blood and skin lesions were obtained from all subjects enrolled in the study.

**AUTHOR CONTRIBUTIONS**

ShuS and ED designed the experiments, analyzed the data, and wrote the manuscript. ShuS and HF performed most of the experiments and analyzed the data. BL and KX participated in the cell experiments. HQ helped with the statistical analyses of some data. JZ, YZ, SheS and TC helped some of the mouse experiments. TZ and PQ performed ELISA detecting inflammatory mediators. CL provided patient samples and data. JG and GW conceived and supervised this study, provided critical suggestions and discussions throughout the study, and revised the manuscript.
FUNDING
This study was supported by the National Natural Science Foundation of China (nos. 81430073 and 81502716).

ACKNOWLEDGMENTS
We thank Jinhong Hu and Xuguo Wang (Department of Pharmacy in Changhai Hospital) for providing K14−VEGF mice and the control FVB/N JCL mice. We also thank the psoriasis patients and healthy donors for their participation in this study.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.00746/full#supplementary-material

REFERENCES
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. (2009) 5:496–509. doi: 10.1056/NEJMra0804595
2. Boehncke W-H, Schön MP. Psoriasis. Lancet. (2015) 386:983–94. doi: 10.1016/s0140-6736 (14)61909-7
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. (2007) 445:866–73. doi: 10.1038/nature05663
4. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. (2012) 7:385–422. doi: 10.1146/annurev-pathol-011811–132448
5. Bagchi S, He Y, Zhang H, Cao L, Van Rhijn I, Moody DB, et al. CD1b-autoreactive T cells contribute to hyperlipidemia-induced skin inflammation in mice. J Clin Invest. (2017) 127:2339–52. doi: 10.1172/JCI92217
6. Di Meglio P, Villanova F, Navarini AA, Mylonas A, Tosi I, Nestle FO, et al. Targeting CD8(+) T cells prevents psoriasis development. J Allergy Clin Immunol. (2016) 138:274–6. doi: 10.1016/j.jaci.2015.04.046
7. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
8. Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, Van Rooijen N, et al. Targeting myeloid lineage cells ameliorates generalized pustular psoriasis in mice. Br J Dermatol. (2006) 155:1144–50. doi: 10.1111/j.1365-2133.2006.07390.x
9. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
10. Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, Van Rooijen N, et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriatic skin inflammation. J Clin Invest. (2006) 112:1609–14. doi: 10.1172/JCI27180
11. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. (2012) 7:385–422. doi: 10.1146/annurev-pathol-011811–132448
12. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
13. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
14. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
15. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
16. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
17. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
18. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
19. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
20. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
21. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
22. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
23. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
24. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
25. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
26. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
27. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
28. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
29. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
30. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
31. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
32. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
33. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
34. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
35. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
36. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
37. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
38. Kirby B. Langerhans cells in psoriasis: getting to the core of the disease. Br J Dermatol. (2018) 178:120–4. doi: 10.1111/bjd.16596
receptors in normal and inflamed human epidermis: up-regulation of dectin-1 in psoriasis. J Invest Dermatol. (2010) 130:2611–20. doi: 10.1038/jid.2010.196

35. Di Candia L, Gomez E, Veneraneu E, Chachi L, Kaur D, Bianchi ME, et al. HMGBl is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4. J Allergy Clin Immunol. (2017) 140:584–7 e8. doi: 10.1016/j.jaci.2016.11.049

36. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation. (2002) 105:685–90. doi: 10.1161/hc0602.103617

37. Conde J, Otero M, Scotece M, Abella V, Lopez V, Pino J, et al. E74-like factor 3 and nuclear factor-kappaB regulate lipocalin-2 expression in chondrocytes. J Physiol. (2016) 594:6133–46. doi: 10.1113/jp227240

38. Ghosh S, Shang P, Yazdankhah M, Blutto I, Hose S, Montezuma SR, et al. Activating the AKT2-nuclear factor-kappaB-lipocalin-2 axis elicits an inflammatory response in age-related macular degeneration. J Pathol. (2017) 241:583–8. doi: 10.1002/path.6870

39. Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-17A and IL-17F are dominant cytokines in generalized pustular psoriasis. J Invest Dermatol. (2015) 135:1025–32. doi: 10.1038/jid.2014.532

40. Mahil SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, et al. Neutrophil extracellular traps induce trypsin activation, inflammation, and superoxide-dependent manner. J Biol Chem. (2016) 291:31361–7. doi: 10.1074/jbc.M116.732018

41. Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. (2011) 365:620–8. doi: 10.1056/NEJMoa1013068

42. Shibata A, Sugiuara K, Furuta Y, Mukumoto Y, Kaminuma O, Akiyama M. Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA. J Autoimmun. (2017) 80:28–38. doi: 10.1016/j.jaut.2017.01.007

43. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36 receptor antagonist deficiency and generalized pustular psoriasis. Nat Med. (2007) 13:1042–9. doi: 10.1038/nm1638

44. Vogl T, Tenbrock K, Ludwig S, Leukurt N, Ehrhardt C, van Zoonen MA, et al. MRP8 and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. (2007) 13:1042–9. doi: 10.1038/nm1638

45. Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, et al. IL-17F and signaling through toll-like receptor 2 and TLR4. J Biol Chem. (2017) 292:10904–11. doi: 10.1074/jbc.M116.749338

46. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Invest Dermatol. (2015) 135:e1000639. doi: 10.1371/journal.ppat.1000639

47. Hoffmann JHO, Schaukel C, Hartl D, Enk AH, Hadaschek EN, Dimethyl fumarate modulates neutrophil extracellular trap formation in a glutathione- and superoxide-dependent manner. Br J Dermatol. (2018) 178:207–14. doi: 10.1111/bjd.15839

48. Liu Y, Carmona-Rivera C, Moore E, Seto NL, Knight JS, Pryor M, et al. Myeloid-specific deletion of peptidylarginine deiminase 4 mitigates atherosclerosis. Front Immunol. (2018) 9:1680. doi: 10.3389/fimmu.2018.01680

49. Wu SL, Demers M, Martinod K, Gallant M, Wang Y, Goldfine AB, et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med. (2015) 21:815–9. doi: 10.1038/nm.3887

50. Kattapur GD, Sundaram MS, Naveenkumar SK, Swethakumar B, Sharma RD, Paul M, et al. NETosis and lack of DNase activity are key factors in Echis carinatus venom-induced tissue destruction. Nat Commun. (2016) 7:11361. doi: 10.1038/ncomms11361

51. Toussaint M, Jackson DJ, Swieboda D, Guedan A, Tsourouktsoglou TD, Mrowiecka M, et al. DNA structures decorated with cathespins G/secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cell implication for psoriasis. J Immunol. (2012) 189:1611–7. doi: 10.4049/jimmunol.1103293

52. Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, et al. IL-1F5, -1F6, -1F8, and -1F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. (2011) 186:2613–22. doi: 10.4049/jimmunol.1003162

53. Skrzeczynska-Moncznik J, Wlodarczyk A, Zabieglo K, Kapinska-Mrowiecka M, Marewicz E, Dubin A, et al. Secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cell implication for psoriasis. J Immunol. (2012) 189:1611–7. doi: 10.4049/jimmunol.1103293